Oramed Pharmaceuticals (NASDAQ:ORMP)‘s stock had its “buy” rating reissued by equities researchers at B. Riley in a research note issued to investors on Monday. They currently have a $20.00 price objective on the biotechnology company’s stock. B. Riley’s price target points to a potential upside of 128.05% from the company’s previous close.
A number of other equities analysts have also commented on the company. ValuEngine lowered Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Oramed Pharmaceuticals in a report on Wednesday, November 22nd.
Oramed Pharmaceuticals (NASDAQ ORMP) opened at $8.77 on Monday. Oramed Pharmaceuticals has a twelve month low of $5.82 and a twelve month high of $11.34.
Several institutional investors have recently bought and sold shares of ORMP. Susquehanna International Group LLP bought a new stake in Oramed Pharmaceuticals during the third quarter valued at $185,000. Virtu KCG Holdings LLC bought a new stake in Oramed Pharmaceuticals during the second quarter valued at $125,000. Finally, Wells Fargo & Company MN boosted its stake in Oramed Pharmaceuticals by 4.4% during the second quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 625 shares during the period. 2.03% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Oramed Pharmaceuticals (ORMP) Rating Reiterated by B. Riley” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.truebluetribune.com/2017/12/13/oramed-pharmaceuticals-ormp-rating-reiterated-by-b-riley.html.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.